📰 Dirk Thye News
Dirk Thye News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dirk Thye. Real-time updates on events, politics, business and more.
May 6, 2024
06.05.2024 - Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., ...
April 1, 2024
Quince Therapeutics, Inc. , a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics,...
February 8, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--$QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince’s Chief Executi...
January 4, 2024
Quince Therapeutics, Inc. , a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today...
October 23, 2023
Quince Therapeutics, Inc. , a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics,...
September 28, 2023
By Denny Jacob Quince Therapeutics said it intends to advance trials on EryDex following the U.S. Food and Drug Administrations hold being lifted on EryDels investigational new drug...
September 28, 2023
Quince Therapeutics, Inc. , a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that the U.S. Food...
September 6, 2023
Quince Therapeutics, Inc. , a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced the appointment of...
August 10, 2023
Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) CEO Dirk Thye purchased 80,000 shares of the stock in a transaction dated Tuesday, August 8th. The stock was bought at an average cost of $1.24 per share, with a total value of $99,200.00. Following the completion of the purchase, the chief executive officer now owns 360,911 […]
August 10, 2023
Quince Therapeutics, Inc. , a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, announced that Dirk Thye, M.D., the... -Today at 04:10 pm- MarketScreener